首页> 美国卫生研究院文献>Pharmaceutics >Improved In Vitro Model for Intranasal Mucosal Drug Delivery: Primary Olfactory and Respiratory Epithelial Cells Compared with the Permanent Nasal Cell Line RPMI 2650
【2h】

Improved In Vitro Model for Intranasal Mucosal Drug Delivery: Primary Olfactory and Respiratory Epithelial Cells Compared with the Permanent Nasal Cell Line RPMI 2650

机译:改进的鼻内粘膜药物递送体外模型:与永久性鼻细胞系RPMI 2650相比原发性嗅觉和呼吸道上皮细胞

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: The epithelial layer of the nasal mucosa is the first barrier for drug permeation during intranasal drug delivery. With increasing interest for intranasal pathways, adequate in vitro models are required. Here, porcine olfactory (OEPC) and respiratory (REPC) primary cells were characterised against the nasal tumour cell line RPMI 2650. Methods: Culture conditions for primary cells from porcine nasal mucosa were optimized and the cells characterised via light microscope, RT-PCR and immunofluorescence. Epithelial barrier function was analysed via transepithelial electrical resistance (TEER), and FITC-dextran was used as model substance for transepithelial permeation. Beating cilia necessary for mucociliary clearance were studied by immunoreactivity against acetylated tubulin. Results: OEPC and REPC barrier models differ in TEER, transepithelial permeation and MUC5AC levels. In contrast, RPMI 2650 displayed lower levels of MUC5AC, cilia markers and TEER, and higher FITC-dextran flux rates. Conclusion: To screen pharmaceutical formulations for intranasal delivery in vitro, translational mucosal models are needed. Here, a novel and comprehensive characterisation of OEPC and REPC against RPMI 2650 is presented. The established primary models display an appropriate model for nasal mucosa with secreted MUC5AC, beating cilia and a functional epithelial barrier, which is suitable for long-term evaluation of sustained release dosage forms.
机译:背景:鼻粘膜的上皮层是鼻内给药过程中药物渗透的第一个障碍。随着对鼻内途径的兴趣的增加,需要适当的体外模型。在这里,针对鼻肿瘤细胞系RPMI 2650鉴定了猪嗅觉(OEPC)和呼吸道(REPC)原代细胞。方法:优化了猪鼻粘膜原代细胞的培养条件,并通过光学显微镜,RT-PCR和免疫荧光。通过跨上皮电阻(TEER)分析上皮屏障功能,FITC-右旋糖酐用作跨上皮渗透的模型物质。通过针对乙酰化微管蛋白的免疫反应性研究了粘膜纤毛清除所需的跳动纤毛。结果:OEPC和REPC屏障模型在TEER,经上皮渗透和MUC5AC水平方面有所不同。相反,RPMI 2650显示出较低水平的MUC5AC,纤毛标记和TEER,以及较高的FITC-葡聚糖通量率。结论:为了筛选用于体外鼻内递送的药物制剂,需要转化粘膜模型。在这里,提出了针对RPMI 2650的OEPC和REPC的新颖而全面的特性。已建立的主要模型显示了具有分泌的MUC5AC,搏动纤毛和功能性上皮屏障的鼻粘膜模型,适用于长期评估缓释剂型。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号